Literature DB >> 16731591

The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.

Zsolt Hodi1, Jayeta Chakrabarti, Andrew H S Lee, John E Ronan, Christopher W Elston, Kwok Leung Cheung, John F R Robertson, Ian O Ellis.   

Abstract

AIM: To assess the reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. Previous studies have mostly been small, with a range of agreement from 62% to 100%.
METHODS: Retrospective audit of 338 tumours surgically excised within 60 days of core biopsy, that had had oestrogen receptor assessed on both the core biopsy and tumour specimens. Surgical specimens were incised when fresh to ensure good fixation. External controls including a weakly positive tumour were included in each immunohistochemistry run.
RESULTS: Oestrogen receptor expression was bimodal, with H score in both specimens of either 0 or >50 in 96% of tumours. Using H score cut-off of 10 for positivity, there was an agreement between core and excision in 334 of 338 tumours (98.8%). All discrepancies were between weakly positive and negative tumours. Intratumoral heterogeneity could explain the one tumour that was negative on core and positive on excision. H score tended to be slightly higher on core than excision (means 146 and 136). Better fixation on the core is the most likely explanation for this and for the three tumours that were positive on core and negative on excision. Repeat staining on tumours with discrepant results gave similar results in all except one case. An internal control was present in 97% of excisions and 55% of cores of oestrogen receptor-negative tumours; the internal control stained positively in all except two sections.
CONCLUSION: Oestrogen receptor can be assessed reliably on needle core biopsies of invasive carcinomas of the breast.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731591      PMCID: PMC1860557          DOI: 10.1136/jcp.2006.036665

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  25 in total

1.  Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions.

Authors:  C Badoual; A Maruani; C Ghorra; P Lebas; S Avigdor; P Michenet
Journal:  Breast       Date:  2005-02       Impact factor: 4.380

2.  Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.

Authors:  Mehrdad Nadji; Carmen Gomez-Fernandez; Parvin Ganjei-Azar; Azorides R Morales
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

3.  Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases.

Authors:  Laura C Collins; Maria L Botero; Stuart J Schnitt
Journal:  Am J Clin Pathol       Date:  2005-01       Impact factor: 2.493

4.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.

Authors:  G Bruce Mann; Vanessa D Fahey; Frank Feleppa; Malcolm R Buchanan
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

6.  Biopathologic profile of breast cancer core biopsy: is it always a valid method?

Authors:  Antonio Cavaliere; Angelo Sidoni; Massimo Scheibel; Guido Bellezza; Giovanni Brachelente; Rino Vitali; Emilio Bucciarelli
Journal:  Cancer Lett       Date:  2005-01-31       Impact factor: 8.679

7.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

8.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.

Authors:  A Rhodes; B Jasani; D M Barnes; L G Bobrow; K D Miller
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

9.  Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?

Authors:  T W Jacobs; K P Siziopikou; J E Prioleau; S Raza; J K Baum; D F Hayes; S J Schnitt
Journal:  Mod Pathol       Date:  1998-03       Impact factor: 7.842

10.  Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.

Authors:  D A Cameron; E D Anderson; P Levack; R A Hawkins; T J Anderson; R C Leonard; A P Forrest; U Chetty
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  14 in total

Review 1.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

2.  Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion.

Authors:  Oxana M Tsygankova; Changqing Ma; Waixing Tang; Christopher Korch; Michael D Feldman; Yu Lv; Marcia S Brose; Judy L Meinkoth
Journal:  Mol Cell Biol       Date:  2010-05-03       Impact factor: 4.272

3.  Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome.

Authors:  William T Barry; Dawn N Kernagis; Holly K Dressman; Ryan J Griffis; J'vonne D Hunter; John A Olson; Jeff R Marks; Geoffrey S Ginsburg; Paul K Marcom; Joseph R Nevins; Joseph Geradts; Michael B Datto
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 4.  Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.

Authors:  Ludmila Prudkin; Paolo Nuciforo
Journal:  Cell Oncol (Dordr)       Date:  2014-09-04       Impact factor: 6.730

5.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.

Authors:  Eitan Amir; Naomi Miller; William Geddie; Orit Freedman; Farrah Kassam; Christine Simmons; Maria Oldfield; George Dranitsaris; George Tomlinson; Andreas Laupacis; Ian F Tannock; Mark Clemons
Journal:  J Clin Oncol       Date:  2011-11-28       Impact factor: 44.544

6.  Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.

Authors:  Ashley S Felix; Roslyn A Stone; Mamatha Chivukula; Robert Bowser; Anil V Parwani; Faina Linkov; Robert P Edwards; Joel L Weissfeld
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

7.  Concomitant use of 18F-FDG PET-CT SUVmax is useful in the assessment of Ki67 labeling index in core-needle biopsy specimens of breast cancer.

Authors:  Hiroki Nakajima; Kazuma Maeno; Tokiko Ito; Toshiharu Kanai; Takaaki Oba; Mayu Ono; Fumiyoshi Takayama; Tsuyoshi Uehara; Ken-Ichi Ito
Journal:  Gland Surg       Date:  2021-01

8.  Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation.

Authors:  T'ng Chang Kwok; Emad A Rakha; Andrew H S Lee; Matthew Grainge; Andrew R Green; Ian O Ellis; Desmond G Powe
Journal:  Histopathology       Date:  2010-08       Impact factor: 5.087

9.  Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables.

Authors:  Yalai Bai; Juliana Tolles; Huan Cheng; Summar Siddiqui; Arun Gopinath; Eirini Pectasides; Robert L Camp; David L Rimm; Annette M Molinaro
Journal:  Lab Invest       Date:  2011-04-25       Impact factor: 5.662

10.  Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.

Authors:  Dana Pape-Zambito; Zhengyu Jiang; Hong Wu; Karthik Devarajan; Carolyn M Slater; Kathy Q Cai; Arthur Patchefsky; Mary B Daly; Xiaowei Chen
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.